References
1. World Health Organization: GlobalTuberculosis Control: Surveilleance, Planning, Financing. WHO report 2005. Geneva, Switzerland, 2005.
2. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLOS Medicine 2006;3:2376-91.
3. Seidler A, Nienhaus A, Diel R. Review of epidemiological studies on the occupational risk of tuberculosis in low-incidence areas. Respiration 2005;2:431-6.
4. Snider DE. Bacille Calmette-Guerin vaccinations and tuberculin skin test. J Am Med Assoc 1985;253:3438-9.
5. Daley AJ, Isaacs D. Differential avian and human tuberculin skin testing in non-tuberculous mycobacterial infection. Arch Dis Child 1999;80:377-9.
6. Huebner RE, Schein MF, Bass JBJ. The tuberculin skin test. Clin Infect Dis 1993;17:968-75.
7. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection. An interferon-γ-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64.
8. Joshi N, Caputo GM. Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999;341:1906-12.
9. Rodriguez-Segade S, Camina MF, Carnero A, Lorenzo MJ, Alban A, Quinteiro C, et al. High serum IgA concentrations in patients with diabetes mellitus: agewise distribution and relation to chronic complications. Clin Chem 1996;42:1064-7.
10. Kanauchi M. Serum IgA levels in patients with diabetic nephropathy and IgA nephropathy superimposed on diabetes mellitus. Diabetes Research and Clinical Practice 2000;48:113-8.
11. King DE, Mainous AG, Buchanan TA, Pearson WS: C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 2003;26:1535–9.
12. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
13. NICE - National Institute for Health and Clinical Excellence. Clinical Guideline 33, Tuberculosis: clinical diagnosis and management of tuberculosis and measurement for its prevention and control. NICE, London, UK, 2006. Available at http://www.nice.org.uk.
14. Mazurek GH, Hereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guideline for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54(RR-15):49-55.
15. Ozdemir D, Annakkaya AN, Tarhan G, Sencan I, Cesur S, Balbay O, et al. Comparison of the tuberculin skin test and the Quantiferon test for latent Mycobacterium tuberculosis infections in health care workrs in Turkey. Jpn J Infect Dis 2007;60:102-5.
16. Nienhaus A, Schablon A, Le Bâcle C, Siano B, Diel R. Evaluation of the interferon-γ release assay in healthcare workers. Int Arch Occup Environ Health 2008;81:295-300.
17. Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T. Screening for tuberculosis infection using whole-blood interferon- γ and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 2006;27:442-8.
18. Kang YA, Lee HW, Yoon HI, Cho BL, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon-γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61.
19. Tissot F, Zanetti G, Francioli P, Zellweger JP, Zysset F. Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005;40:211-7.
20. Bugiani M, Borraccino A, Migliore E, Carosso A, Piccioni P, Cavallero M, et al. Tuberculin reactivity in adult BCG-vaccinated subjects: a cross-sectional study. Int J Tuberc Lung Dis 2003;7:320-6.
21. Arend SM, Thijsen SFT, Leyten EMS, Bouwman JJM, Franken WPJ, Koster BFPJ, et al. Comparison of two interferon-γ assays and tuberculin skin test for tracing tuberculosis contacts. Am J Resp Crit Care Med 2007;175:618-27.
22. Menzies D. Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15–21.
23. Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, Fujii M, et al. Usefulness of QuantiFERON TB-2G, a diagnostic method for latent tuberculosis infection, in a contact investigation of health care workers. Intern Med 2007;46;1543-9.
24. Streeton JA, Desem N, Jones SL. Sensitivity and specificity of gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 1998;2:435-50.
25. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis. Expert Rev Mol Diagn 2006;6:413-22.
26. Pai M, Gokhale K, Joshi R, Dogra S, Kalantri S, Mendiratta DK. Mycobacterium tuberculosis Infection in health care workers in rural India. Comparison of a whole-blood - γ assay with tuberculin skin testing. JAMA 2005;293:2746-55.
27. Madariaga MG, Jalali Z, Swindells S. Clinical utility of interfereon gamma assay in the diagnosis of tuberculosis. J Am Board Fam Med 2007;20:540-7.
28. Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 2007;30:945-50.
29. Broxmeyer L. Diabetes mellitus, tuberculosis and the mycobacteria: Two millenia of enigma. Med Hypotheses 2005;65:433-9.
30. Gupta S, Koirala J, Khardori R, Khardori N. Infections in diabetes mellitus and hyperglycemia. Inf Dis Clin North Am 2007;21:617-38.
31. Martens FW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis susceptibiliy of diabetic mice. Am J Respir Cell Mol Biol 2007;37:518-24.
32. Stalenhoef JE, Alisjahbana B, Nelwan EJ, van der Ven-Jongerkrijg J, Ottenhoff TH, van der Meer JW, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis 2008;27:97-103.